CJC-1295 DAC
Once-weekly GHRH — albumin-binding DAC extends half-life to 6–8 days for sustained GH and IGF-1 elevation.
Research facts
| Half-life | 6–8 days |
|---|---|
| Route | SubQ |
| Typical dose | 1–2 mg/week |
| Frequency | Once weekly |
| Solvent | Bacteriostatic water |
| pH | 5.0–7.0 |
| Stability | 30 days at +4°C |
Mechanism of action
CJC-1295 DAC contains the same GHRH(1-29) sequence as the no-DAC version, but incorporates a Drug Affinity Complex — a Lys-maleimide-biotin linker that covalently binds to plasma albumin in the bloodstream. This dramatically extends the active half-life to 6–8 days, producing sustained GH and IGF-1 elevation rather than pulsatile release.
Once-weekly administration maintains elevated mean 24-hour GH and IGF-1 levels, providing a more anabolic background state than pulsatile GHRH. The sustained elevation pattern is less physiological than endogenous pulsatility but potentially more convenient and consistently anabolic. Bryan Johnson documented use of Tirzepatide + CJC-1295 DAC in 2025 as an experimental body composition stack.
Documented effects (research-model)
- Sustained IGF-1 elevation from once-weekly dosing
- Body composition improvement via sustained GH axis activation
- Convenience: weekly rather than daily injection
- Anti-ageing via prolonged GH/IGF-1 axis support
- Sleep quality research
Research protocols
| Protocol | Dose | Frequency | Cycle | Vial |
|---|---|---|---|---|
| Standard | 1 mg once/week | Once weekly SubQ | 12 weeks | 5mg / 2mL BAC water |
| Advanced | 2 mg/week split 2× | Twice weekly | 12 weeks | 5mg / 2mL BAC water |
Research context only. Not medical advice. Consult a qualified healthcare professional before any protocol decision.
Synergies
- Ipamorelin MODERATE
Sustained GH background (DAC) + triggered pulses (Ipamorelin). Many prefer no-DAC for more physiological pulsatility. - Tesamorelin LOW
Both GHRH analogues — redundant if combined.
Myths & misconceptions
Evidence gaps
- No comparative data between DAC and no-DAC versions for specific outcomes in humans.
- The sustained GH elevation pattern's long-term safety vs. pulsatile remains unknown.
- Optimal dose in combination protocols not established.
Safety notes
Removed from FDA Category 2 April 2026. The sustained GH elevation warrants careful IGF-1 monitoring. Water retention possible. Less physiological than no-DAC version.
Biomarkers to monitor
Primary-source citations
- PMID 17270313 — Effects of a long-acting GHRH analog on 24-hour growth hormone secretion (J Clin Endocrinol Metab. 2007)
Frequently asked
What is CJC-1295 DAC?
CJC-1295 DAC (Long-Acting GHRH with Drug Affinity Complex) is a research compound classified in our library as Tier B — Some human data + strong preclinical evidence.. Once-weekly GHRH — albumin-binding DAC extends half-life to 6–8 days for sustained GH and IGF-1 elevation.
What is the evidence tier for CJC-1295 DAC?
We classify CJC-1295 DAC as Tier B: Some human data + strong preclinical evidence. See our full peptide evidence tiers explainer for how we assign S/A/B/C/D.
What is the research dose of CJC-1295 DAC?
For CJC-1295 DAC, typical research dose is 1–2 mg/week, route is SubQ, half-life is 6–8 days. Protocols vary by research goal — see the protocols section on this page for standard and advanced dosing schedules. Research use only, not medical advice.
Is CJC-1295 DAC safe?
Removed from FDA Category 2 April 2026. The sustained GH elevation warrants careful IGF-1 monitoring. Research context only — no compound on this site is approved for human therapeutic use unless explicitly noted.